MA44513B1 - Formulations injectables de fosnetupitant physiologiquement equilibrees - Google Patents

Formulations injectables de fosnetupitant physiologiquement equilibrees

Info

Publication number
MA44513B1
MA44513B1 MA44513A MA44513A MA44513B1 MA 44513 B1 MA44513 B1 MA 44513B1 MA 44513 A MA44513 A MA 44513A MA 44513 A MA44513 A MA 44513A MA 44513 B1 MA44513 B1 MA 44513B1
Authority
MA
Morocco
Prior art keywords
fosnetupitant
physiologically balanced
injectable formulations
balanced injectable
formulations
Prior art date
Application number
MA44513A
Other languages
English (en)
Inventor
Roberta Cannella
Alessio Venturini
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59055193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44513(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA44513B1 publication Critical patent/MA44513B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des doses et des formulations injectables de fosnétupitant et de sels de qualité pharmaceutique de celui-ci, qui sont efficaces, chimiquement stables et physiologiquement équilibrées pour plus de sécurité et d'efficacité.
MA44513A 2016-06-06 2017-06-01 Formulations injectables de fosnetupitant physiologiquement equilibrees MA44513B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345942P 2016-06-06 2016-06-06
PCT/EP2017/063268 WO2017211663A1 (fr) 2016-06-06 2017-06-01 Formulations injectables physiologiquement équilibrées de fosnétupitant
EP17729822.1A EP3435980B1 (fr) 2016-06-06 2017-06-01 Formulations injectables de fosnetupitant physiologiquement equilibrees

Publications (1)

Publication Number Publication Date
MA44513B1 true MA44513B1 (fr) 2020-02-28

Family

ID=59055193

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44513A MA44513B1 (fr) 2016-06-06 2017-06-01 Formulations injectables de fosnetupitant physiologiquement equilibrees

Country Status (37)

Country Link
US (5) US10624911B2 (fr)
EP (2) EP3626231A1 (fr)
JP (2) JP6936817B2 (fr)
KR (1) KR102459416B1 (fr)
CN (1) CN109310627B (fr)
AR (1) AR108676A1 (fr)
AU (1) AU2017276588B2 (fr)
BR (1) BR112018074655B1 (fr)
CA (1) CA3025837C (fr)
CL (1) CL2018003338A1 (fr)
CO (1) CO2018011686A2 (fr)
CY (1) CY1122755T1 (fr)
DK (1) DK3435980T3 (fr)
EA (1) EA036605B1 (fr)
EC (1) ECSP19000169A (fr)
ES (1) ES2771226T3 (fr)
GE (1) GEP20207189B (fr)
HR (1) HRP20200196T1 (fr)
IL (1) IL263126B (fr)
JO (1) JOP20170137B1 (fr)
LT (1) LT3435980T (fr)
MA (1) MA44513B1 (fr)
MD (1) MD3435980T2 (fr)
MX (1) MX376118B (fr)
MY (1) MY194081A (fr)
PE (1) PE20190347A1 (fr)
PH (1) PH12018502524B1 (fr)
PL (1) PL3435980T3 (fr)
PT (1) PT3435980T (fr)
RS (1) RS59852B1 (fr)
SG (1) SG11201809708PA (fr)
SI (1) SI3435980T1 (fr)
TW (1) TWI725191B (fr)
UA (1) UA122285C2 (fr)
UY (1) UY37273A (fr)
WO (1) WO2017211663A1 (fr)
ZA (1) ZA201807932B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11654154B2 (en) 2019-01-29 2023-05-23 Navinta Iii Inc Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
JP7783403B2 (ja) * 2022-03-23 2025-12-09 大鵬薬品工業株式会社 ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法
CN121666239A (zh) * 2023-08-13 2026-03-13 赫尔森保健股份公司 用于通过静脉内推注施用的福奈妥匹坦
WO2025056094A1 (fr) * 2023-09-15 2025-03-20 广州帝奇医药技术有限公司 Préparation lyophilisée, injection, et procédé de préparation associé
US20250387420A1 (en) 2024-06-24 2025-12-25 Helsinn Healthcare Sa Prevention of Nausea and Vomiting from Antibody-Drug Conjugates and other Long-Acting Emetogenics
CN119185243A (zh) * 2024-11-28 2024-12-27 山东齐都药业有限公司 福奈妥匹坦帕洛诺司琼口服掩味颗粒剂及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642178B2 (en) * 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
WO2013057554A2 (fr) * 2011-10-18 2013-04-25 Helsinn Healthcare Sa Combinaisons thérapeutiques de nétupitant et de palonosétron
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US20150165045A1 (en) * 2012-07-06 2015-06-18 Pharmathen S.A. Stable injectable pharmaceutical composition of neurokinin 1 receptor antagonist and process for preparation thereof
EP2931253A1 (fr) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Composition pharmaceutique comprenant des composés antiémétiques et un polyorthoesther

Also Published As

Publication number Publication date
DK3435980T3 (da) 2020-02-24
UY37273A (es) 2018-01-31
GEAP202014974A (en) 2020-07-27
CA3025837C (fr) 2024-02-13
MD3435980T2 (ro) 2020-03-31
MX376118B (es) 2025-03-07
KR102459416B1 (ko) 2022-10-27
JP2021183639A (ja) 2021-12-02
ECSP19000169A (es) 2019-01-31
WO2017211663A1 (fr) 2017-12-14
PH12018502524A1 (en) 2019-10-14
JOP20170137B1 (ar) 2021-08-17
CY1122755T1 (el) 2021-03-12
EA036605B1 (ru) 2020-11-27
CA3025837A1 (fr) 2017-12-14
CN109310627B (zh) 2021-12-14
US20230172953A1 (en) 2023-06-08
GEP20207189B (en) 2020-12-10
TW201801727A (zh) 2018-01-16
UA122285C2 (uk) 2020-10-12
SG11201809708PA (en) 2018-11-29
CO2018011686A2 (es) 2019-02-08
ES2771226T3 (es) 2020-07-06
JP7223084B2 (ja) 2023-02-15
SI3435980T1 (sl) 2020-03-31
HRP20200196T1 (hr) 2020-05-01
US11529362B2 (en) 2022-12-20
BR112018074655B1 (pt) 2024-02-15
US20200206249A1 (en) 2020-07-02
US10624911B2 (en) 2020-04-21
MY194081A (en) 2022-11-11
CL2018003338A1 (es) 2019-02-22
RS59852B1 (sr) 2020-02-28
PH12018502524B1 (en) 2022-04-27
IL263126A (en) 2018-12-31
AU2017276588B2 (en) 2022-06-02
EP3626231A1 (fr) 2020-03-25
PT3435980T (pt) 2020-02-21
US12208109B2 (en) 2025-01-28
AR108676A1 (es) 2018-09-12
NZ747865A (en) 2024-05-31
JP6936817B2 (ja) 2021-09-22
BR112018074655A2 (pt) 2019-03-06
EA201892837A1 (ru) 2019-06-28
MX2018015036A (es) 2019-04-11
US20250235473A1 (en) 2025-07-24
ZA201807932B (en) 2019-08-28
PL3435980T3 (pl) 2020-05-18
AU2017276588A1 (en) 2018-11-22
LT3435980T (lt) 2020-02-25
EP3435980A1 (fr) 2019-02-06
PE20190347A1 (es) 2019-03-07
KR20190015276A (ko) 2019-02-13
TWI725191B (zh) 2021-04-21
JP2019521102A (ja) 2019-07-25
US20260027138A1 (en) 2026-01-29
US20170348335A1 (en) 2017-12-07
CN109310627A (zh) 2019-02-05
IL263126B (en) 2021-04-29
EP3435980B1 (fr) 2019-11-13

Similar Documents

Publication Publication Date Title
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BR112017004393A2 (pt) formulações de anticorpo
MX2017016555A (es) Compuestos inhibidores de la señalizacion de la via de notch.
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018011788A (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
JOP20230099A1 (ar) تركيبات صيدلية
EA201990162A1 (ru) Фармацевтические композиции
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид